PMV Pharma

www.pmvpharma.comPrinceton, NJ, United StatesMember of HARO Newswire since
Releases
1
First release
Most recent
Categories
Nasdaq:PMVP

Press releases from PMV Pharma

Tagged nasdaq pmvpClear

1 release

  1. Nasdaq:PMVP

    PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors

    48% confirmed overall response rate (ORR) with a 10.4-month median duration of response in the primary analysis population of 65 patients with platinum-resistant/refractory ovarian cancer 36% ORR with an 8.1-month median duration of response across all cohorts in the overall…

    PMV Pharma News Releases | HARO Newswire